Institutions Profited After Erasca, Inc.'s (NASDAQ:ERAS) Market Cap Rose US$169m Last Week but Retail Investors Profited the Most
Erasca Kicks off Phase III Trial for Naporafenib Combo Therapy in Melanoma
Express News | Erasca Inc - Favorable Mos and Mpfs Demonstrated in Pooled Analysis of Phase 1B and Phase 2 Trials in Nrasm Melanoma
Express News | Erasca Inc - Randomized Stage 1 Readout for Naporafenib Plus Trametinib Vs. Trametinib Monotherapy Expected in 2025
Express News | Erasca Initiates Seacraft-2 Pivotal Phase 3 Trial Evaluating Naporafenib Plus Trametinib in Patients With Nras-Mutant Melanoma
Erasca Initiates SEACRAFT-2 Pivotal Phase 3 Trial Evaluating Naporafenib Plus Trametinib in Patients With NRAS-Mutant Melanoma
Erasca to Present at Upcoming Investor Conferences in June
Erasca Is Maintained at Buy by Goldman Sachs
Goldman Sachs Maintains Buy on Erasca, Lowers Price Target to $4
E.l.f. Beauty Posts Upbeat Earnings, Joins Nvidia, LiveRamp Holdings, Borr Drilling And Other Big Stocks Moving Higher On Thursday
Jaguar Health, Altamira Therapeutics,Erasca Among Healthcare Movers
$1.5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
Insider Spends US$182k Buying More Shares In Erasca
Independent Director of Erasca Picks Up 14% More Stock
Erasca(ERAS.US) Director Buys US$181.92K in Common Stock
Erasca Closes Oversubscribed Share Offering to Raise $184 Million
Press Release: Erasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares
Erasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares
Erasca's Strategic Advances and Financial Fortitude Merit a Buy Rating
Erasca Is Maintained at Buy by HC Wainwright & Co.